Skip to main content
Fig. 1 | BMC Neurology

Fig. 1

From: Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East

Fig. 1

Mean (±SD) change in MusiQoL scores from baseline to Months (a) 6 and (b) 12 (FAS). *No. of pairs. Displayed is the difference in mean between the baseline score and the score of the evaluation time (a negative difference indicates a QoL improvement and a positive difference indicates a QoL deterioration). DMT, disease-modifying treatment; CI, confidence interval; FAS, full analysis set; LL, lower limit; MusiQoL, Multiple Sclerosis International Quality of Life; QoL, quality of life; SD, standard deviation; UL, upper limit

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us